Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. (2022)
Attributed to:
King's Health Partners Confidence in Concept
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/ecco-jcc/jjab153
PubMed Identifier: 34473254
Publication URI: http://europepmc.org/abstract/MED/34473254
Type: Journal Article/Review
Volume: 16
Parent Publication: Journal of Crohn's & colitis
Issue: 3
ISSN: 1873-9946